Document:

EX-10.1

 Exhibit 10.1 

EXECUTIVE EMPLOYMENT AGREEMENT 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into between NUCOR CORPORATION, a Delaware
corporation with its principal place of business in Charlotte, North Carolina, on behalf of itself and each of its affiliates and subsidiaries (all such entities, collectively, “Nucor”), and CRAIG FELDMAN
(“Executive”), a resident of Ohio as of the date hereof, but who will be relocating to the Charlotte, North Carolina area pursuant to the performance of his duties following his promotion discussed herein. 

WHEREAS, Executive has heretofore been employed at Nucor Corporation’s The David J. Joseph Company subsidiary as an at-will employee of Nucor in the position of Vice President of Nucor Corporation and President of The David J. Joseph Company (the “Prior Position”); and 

WHEREAS, Nucor has offered Executive a promotion to the position of Executive Vice President of Nucor Corporation and President of The David
J. Joseph Company effective June 10, 2018 (the “Effective Date”), contingent upon Executive’s execution of this Agreement, and Executive has accepted the promotion; and 

WHEREAS, Nucor Corporation’s Board of Directors (the “Board”) has approved Executive’s promotion to the position of
Executive Vice President of Nucor Corporation and President of The David J. Joseph Company contingent upon Executive’s execution of this Agreement; and 

WHEREAS, prior to the effective date of the promotion, Executive and Nucor discussed the requirements of the restrictive covenants contained
in this Agreement as a condition to Executive’s promotion; and 
 WHEREAS, Nucor’s promotion of Executive entitles Executive to
receive increased compensation and benefits that Executive did not have prior to his promotion; and 
 WHEREAS, Executive agrees and
acknowledges that in his new position of Executive Vice President of Nucor Corporation and President of The David J. Joseph Company he will acquire greater access to and knowledge of Nucor’s trade secrets and confidential information which
Executive did not have prior to his promotion; and 
 WHEREAS, the parties wish to formalize their employment relationship in writing and
for Nucor to employ Executive under the terms and conditions set forth below; and 
 NOW, THEREFORE, in consideration for the promises and
mutual agreements contained herein, the parties agree, effective as of the Effective Date, as follows: 

1.    Employment. Nucor agrees to employ Executive in the position of Executive Vice President of Nucor Corporation
and President of The David J. Joseph Company, and Executive agrees to accept employment in this position, subject to the terms and conditions set forth in this Agreement, including the confidentiality,
non-competition and non-solicitation provisions which Executive acknowledges were discussed in detail prior to and made an express condition of his promotion to
Executive Vice President of Nucor Corporation and President of The David J. Joseph Company. Executive acknowledges that the Board’s approval of Executive’s promotion to Executive Vice President of Nucor Corporation and President of The
David J. Joseph Company is conditioned upon Executive’s execution of this Agreement. 

 2.    Compensation and Benefits During Employment. Nucor will provide
the following compensation and benefits to Executive: 
 (a)    Nucor will pay Executive a base salary of
$436,100 per year, paid not less frequently than monthly in accordance with Nucor’s normal payroll practices, subject to withholding by Nucor and other deductions as required by law. The parties acknowledge and agree that this amount exceeds
the base salary Executive was entitled to receive in the Prior Position. Executive’s base salary is subject to adjustment up or down by the Board at its sole discretion and without notice to Executive. 

(b)    Provided Executive remains in the position of an executive officer of Nucor Corporation, Executive
will be a participant in and eligible to receive awards of incentive and equity-based compensation under and in accordance with the applicable terms and conditions of the Nucor Corporation Senior Officers Annual Incentive Plan, the Nucor Corporation
Senior Officers Long-Term Incentive Plan, and the Nucor Corporation 2014 Omnibus Incentive Compensation Plan (the “Omnibus Plan”), each as modified from time to time by, and in the sole discretion of, the Board of Directors of Nucor
Corporation. 
 (c)    Provided Executive remains in the position of an executive officer of Nucor
Corporation, Executive will be eligible for all other employee benefits that are generally made available by Nucor Corporation to its executive officers. To the extent Executive is eligible to participate in the Nucor Corporation Severance Plan for
Senior Officers and General Managers (the “Severance Plan”) pursuant to its terms, notwithstanding anything to the contrary set forth in the Severance Plan, Executive’s years of service with The David J. Joseph Company prior to such
time as The David J. Joseph Company became a subsidiary of Nucor Corporation shall be deemed Years of Service (as such term is defined in the Severance Plan). 

3.    Compensation Following Termination. 

(a)    From the date of Executive’s termination of employment with Nucor, whether by Executive or
Nucor for any or no reason, and provided that (i) Executive executes and returns to Nucor a separation and release agreement in form and substance satisfactory to Nucor, in its sole discretion, releasing any and all claims Executive has or may
have against Nucor at the time of his termination of employment from Nucor, (ii) Executive is employed as an Executive Vice President of Nucor at the time of Executive’s termination of employment with Nucor, and (iii), except in the event
Executive’s employment with Nucor is terminated in accordance with applicable laws, rules and regulations due to Executive’s disability, Executive is at least fifty eight (58) years of age and has served as an Executive Vice President
of Nucor for at least five (5) consecutive years at the time of Executive’s termination of employment with Nucor (the “Monthly Payment Requirements”), Nucor will pay Executive the Monthly Amount (as defined below) for
twenty-four (24) months following Executive’s termination. Nucor shall have no obligation to make any payments of the Monthly Amount if, at the time of Executive’s termination of employment with Nucor, all of the Monthly Payment
Requirements are not satisfied. The “Monthly Amount” shall be an amount equal to (i) the product of (A) the amount of Executive’s highest base salary level during the twelve (12) month period immediately prior to
his date of termination, multiplied by (B) 3.36, (ii) divided by twelve (12). Subject to the provisions of Section 24 of this Agreement, the payments of any Monthly Amount due shall be made at the end of each month following Executive’s
termination of employment with Nucor on Nucor’s regular monthly payroll date. 

  
 2 

 (b)    In exchange for Nucor’s agreement to pay the
Monthly Amount as set forth in this Section 3, and other good and valuable consideration, including without limitation the compensation and benefits set forth in Section 2 of this Agreement, Executive agrees to strictly abide by the terms
of Sections 8 through 13 of this Agreement. 
 (c)    If Executive is employed by Nucor at the time of
Executive’s death, Nucor’s obligations to make any payments of the Monthly Amount under this Agreement will automatically terminate and Executive’s estate and executors will have no rights to any payments of the Monthly Amount under
this Agreement. If Executive dies during the first twelve (12) months following Executive’s termination from employment with Nucor, then Nucor will pay Executive’s estate the payments of the Monthly Amount due pursuant to
Section 3(a) of this Agreement through the end of the twelfth (12th) month following Executive’s termination from employment with Nucor. If Executive dies twelve (12) or more months
after termination of Executive’s employment with Nucor, then Nucor’s obligations to make any payments of the Monthly Amount under Section 3(a) of this Agreement will automatically terminate without the necessity of Nucor providing
notice, written or otherwise. 
 (d)    The amounts payable pursuant to this Section 3 of this
Agreement shall be in addition to and not in lieu of any amounts payable to Executive pursuant to the Nucor Corporation Severance Plan for Senior Officers and General Managers (the “Severance Plan”), which payments, if any, shall be
governed by the terms and conditions of the Severance Plan. 
 4.    Duties and Responsibilities; Best Efforts.
While employed by Nucor, Executive shall perform such duties for and on behalf of Nucor as may be determined and assigned to Executive from time to time by the Chief Executive Officer of Nucor Corporation or the Board. Executive shall devote his
full time and best efforts to the business and affairs of Nucor. During the term of Executive’s employment with Nucor, Executive will not undertake other paid employment or engage in any other business activity without the prior written consent
of the Board. 
 5.    Employment at Will. The parties acknowledge and agree that this Agreement does not create
employment for a definite term and that Executive’s employment with Nucor is at will and terminable by Nucor or Executive at any time, with or without cause and with or without notice, unless otherwise expressly set forth in a separate written
agreement executed by Executive and Nucor after the Effective Date. 
 6.    Change in Executive’s Position.
In the event that Nucor transfers, demotes, promotes, or otherwise changes Executive’s compensation or position with Nucor, the restrictions and post-termination obligations set forth in Sections 8 through 13 of this Agreement shall remain in
full force and effect. 
 7.    Recognition of Nucor’s Legitimate Interests. Executive understands and
acknowledges that Nucor competes in North America and throughout the world in the research, manufacture, marketing, trading, brokering, recycling, placement, processing, sale, fabrication, placement and/or distribution of steel or steel products
(including but not limited to flat-rolled steel, special quality and merchant quality steel bar and shapes, concrete reinforcement bars, structural steel, hollow structural section tubing, conduit tubing, steel plate, steel joists and girders, steel
deck, steel fasteners, steel pilings, metal building systems, wire rod, welded-wire reinforcement rolls and sheets, cold finished steel bars and wire, guard rail, and structural welded-wire reinforcement) or steel or steel product inputs (including
but not limited to directed reduced iron and ferrous and non-ferrous scrap metal and substitutes thereof) (all such activities, collectively, the “Business”). As part of Executive’s
employment with Nucor, Executive acknowledges he will continue to have access to and gain knowledge of significant secret, confidential and proprietary information of the full range of operations of Nucor. In addition, Executive will continue

  
 3 

 
to have access to training opportunities, contact with vendors, suppliers, customers and prospective vendors, suppliers and customers of Nucor, in which capacity he is expected to develop good
relationships with such vendors, suppliers, customers and prospective vendors, suppliers and customers, and will gain intimate knowledge regarding the products and services of Nucor. Executive recognizes and agrees that Nucor has spent and will
continue to spend substantial effort, time and money in developing relationships with its vendors, suppliers and customers, that many such vendors, suppliers and customers have long term relationships with Nucor, and that all vendors, suppliers,
customers and accounts that Executive may deal with during his employment with Nucor, are the vendors, suppliers, customers and accounts of Nucor. Executive acknowledges that Nucor’s competitors would obtain an unfair advantage if Executive
disclosed Nucor’s Secret Information or Confidential Information (as defined in Sections 8 and 9, respectively) to a competitor, used it on a competitor’s behalf, or if he were able to exploit the relationships he develops as an employee
of Nucor to solicit business on behalf of a competitor. 
 8.    Covenant Regarding Nucor’s Secret
Information. Executive recognizes and agrees that he will have continued access to certain sensitive and confidential information of Nucor (a) that is not generally known in the steel business, which would be difficult for others to acquire
or duplicate without improper means, (b) that Nucor strives to keep secret, and (c) from which Nucor derives substantial commercial benefit because of the fact that it is not generally known (the “Secret Information”),
including without limitation: (i) Nucor’s process of developing, processing, recycling and producing raw material, and designing and manufacturing steel and iron products; (ii) Nucor’s process for treating,
processing or fabricating steel and iron products; (iii) Nucor’s non-public financial data, trading or brokering data and strategies, strategic business plans, competitor analysis, sales and
marketing data, and proprietary margin, pricing, and cost data; and (iv) any other information or data which meets the definition of “trade secrets” under the North Carolina Trade Secrets Protection Act. Executive agrees that unless
he is expressly authorized by Nucor in writing, Executive will not use or disclose or allow to be used or disclosed Nucor’s Secret Information. This covenant shall survive until the Secret Information is generally known in the industry through
no act or omission of the Executive or until Nucor knowingly authorizes the disclosure of or discloses the Secret Information, without any limitations on use or confidentiality. Executive acknowledges that he did not have knowledge of Nucor’s
Secret Information prior to his employment with Nucor and that the Secret Information does not include Executive’s general skills and know-how. 

Notwithstanding the foregoing, pursuant to the federal Defend Trade Secrets Act of 2016, an individual will be immune from criminal or civil liability under
any federal or state trade secret law for (x) the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the
purpose of reporting or investigating a suspected violation of law; or (y) a disclosure that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit
for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing
the trade secret under seal and does not disclose the trade secret, except pursuant to court order 
 9.    Agreement
to Maintain Confidentiality. 
 (a)    As used in this Agreement, “Confidential
Information” shall include all confidential and proprietary information of Nucor, including, without limitation, any of the following information to the extent not generally known to third persons: financial and budgetary information and
strategies; plant design, specifications, and layouts; equipment design, specifications, and layouts; product design and specifications; manufacturing, processing and 

  
 4 

 
recycling processes, procedures, and specifications; data processing or other computer programs; research and development projects; marketing information and strategies; customer lists; vendor
lists; supplier lists; information about supplier preferences and supply patterns; information about customer preferences and buying patterns; information about prospective customers, vendors, suppliers or prospective business opportunities;
information about Nucor’s costs and the pricing structure used in sales to customers or purchases from suppliers; information about Nucor’s overall corporate business strategy; and technological innovations used in Nucor’s business,
to the extent that such information does not fall within the definition of Secret Information. 

(b)    During Executive’s employment with Nucor and at all times after the termination of
Executive’s employment with Nucor, (i) Executive covenants and agrees to treat as confidential all Confidential Information submitted to Executive or received, compiled, developed, designed, produced, accessed, or otherwise discovered by
the Executive from time to time while employed by Nucor, and (ii) Executive will not disclose or divulge the Confidential Information to any person, entity, firm or company whatsoever or use the Confidential Information for Executive’s own
benefit or for the benefit of any person, entity, firm or company other than Nucor. This restriction will apply throughout the world; provided, however, that if the restrictions of this Section 9(b) when applied to any
specific piece of Confidential Information would prevent Executive from using his general knowledge or skills in competition with Nucor or would otherwise substantially restrict the Executive’s ability to fairly compete with Nucor, then as to
that piece of Confidential Information only, the scope of this restriction will apply only for the Restrictive Period (as defined below). 

(c)    Executive specifically acknowledges that the Confidential Information, whether reduced to writing or
maintained in the mind or memory of Executive, and whether compiled or created by Executive, Nucor, or any of its vendors, suppliers, customers, or prospective vendors, suppliers or customers derives independent economic value from not being readily
known to or ascertainable by proper means by others who could obtain economic value from the disclosure or use of the Confidential Information. Executive also acknowledges that reasonable efforts have been put forth by Nucor to maintain the secrecy
of the Confidential Information, that the Confidential Information is and will remain the sole property of Nucor or any of its vendors, suppliers, customers or prospective vendors, suppliers or customers, as the case may be, and that any retention
and/or use of Confidential Information during or after the termination of Executive’s employment with Nucor (except in the regular course of performing his duties hereunder) will constitute a misappropriation of the Confidential Information
belonging to Nucor. Executive acknowledges and agrees that if he (i) accesses Confidential Information on any Nucor computer system within 30 days prior to the effective date of his voluntary resignation of employment with Nucor and
(ii) transmits, copies or reproduces in any manner such Confidential Information to or for himself or any person or entity not authorized by Nucor to receive such Confidential Information, or deletes any such Confidential Information, he is
exceeding his authorized access to such computer system. Notwithstanding anything to the contrary set forth herein, this Agreement shall not be construed to restrict Executive from communications or disclosures that are protected under federal law
or regulation. 

  
 5 

 10.    Noncompetition. 

(a)    Executive hereby agrees that for the duration of Executive’s employment with Nucor, and for a
period of twenty-four (24) months thereafter (the “Restrictive Period”), Executive will NOT, either individually or through or by any agent, representative, entity, employee or otherwise, within the Restricted Territory, do any
of the following: 
 (i)    engage in, whether as an employee, consultant, or in any other capacity, any
business activity (other than business activities engaged in for or on behalf of Nucor) (A) that is the same as, or is in direct competition with, any portion of the Business, and (B) in which Executive engaged in during the course of his
employment with Nucor (any such activities described in this Section 10(a)(i), “Competing Activities”); 

(ii)    commence, establish or own (in whole or in part) any business that engages in any Competing
Activities, whether (i) by establishing a sole proprietorship, (ii) as a partner of a partnership, (iii) as a member of a limited liability company, (iv) as a shareholder of a corporation (except to the extent Executive is the
holder of not more than five percent (5%) of any class of the outstanding stock of any company listed on a national securities exchange so long as Executive does not actively participate in the management or business of any such entity) or
(v) as the owner of any similar equity interest in any such entity; 
 (iii)    provide any public
endorsement of, or otherwise lend Executive’s name for use by, any person or entity engaged in any Competing Activities; or 

(iv)    engage in work that would inherently call on him in the fulfillment of his duties and
responsibilities to reveal, rely upon, or otherwise use any Confidential Information or Secret Information. 

(b)    For purposes of this Agreement: 

(i)    The term “Restricted Territory” means Executive’s geographic area of
responsibility at Nucor which Executive acknowledges extends to the full scope of Nucor operations throughout the world. “Restricted Territory” therefore consists of the following alternatives reasonably necessary to protect
Nucor’s legitimate business interests: 
 (A)    Western Europe, the Middle East, South America,
Central America and North America, where Executive acknowledges Nucor engages in the Business, but if such territory is deemed overbroad by a court of law, then 

(B)    The United States, Canada, Mexico, Guatemala, Honduras, the Dominican Republic, Costa Rica,
Colombia, Argentina and Brazil, where Executive acknowledges Nucor engages in the Business, but if such territory is deemed overbroad by a court of law, then; 

(C)    The United States, Canada and Mexico, where Executive acknowledges Nucor engages in the Business,
but if such territory is deemed overbroad by a court of law, then; 
 (D)    The contiguous United
States, where Executive acknowledges Nucor engages in the Business, but if such territory is deemed overbroad by a court of law, then; 

(E)    Any state in the United States located within a three hundred (300) mile radius of a Nucor
plant or facility that engages in any aspect of the Business, but if such territory is deemed overbroad by a court of law, then; 

  
 6 

 (F)    Any state in the United States where a Customer or
Supplier or Prospective Customer or Supplier is located. 
 (ii)    The term “Customer or
Supplier” means the following alternatives: 
 (A)    any and all customers or suppliers of
Nucor with whom Nucor is doing business at the time of, or at any time during the 12 month period immediately prior to, Executive’s termination of employment with Nucor, but if such definition is deemed overbroad by a court of law, then; 

(B)    any customer or supplier of Nucor with whom Executive or Executive’s direct reports had
significant contact or with whom Executive or Executive’s direct reports directly dealt on behalf of Nucor at the time of, or at any time during the 12 month period immediately prior to, Executive’s termination of employment with Nucor,
but if such definition is deemed overbroad by a court of law, then; 
 (C)    any customer or supplier
of Nucor with whom Executive had significant contact or with whom Executive directly dealt on behalf of Nucor at the time of, or at any time during the 12 month period immediately prior to, Executive’s termination of employment with Nucor, but
if such definition is deemed overbroad by a court of law, then; 
 (D)    any customer or supplier of
Nucor about whom Executive had obtained Secret Information or Confidential Information by virtue of his employment with Nucor and with whom Executive had significant contact or with whom Executive directly dealt on behalf of Nucor at the time of, or
at any time during the 12 month period immediately prior to, Executive’s termination of employment with Nucor; 

Provided, however, that the term “Customer or Supplier” shall not include any business or entity that
no longer does business with Nucor without any direct or indirect interference by Executive or violation of this Agreement by Executive, and that ceased doing business with Nucor prior to any direct or indirect communication or contact by Executive.

 (iii)     The term “Prospective Customer or Supplier” means any person or entity who
does not currently or has not yet purchased the products or services of Nucor or from whom Nucor does not currently or has not yet purchased products or services, but who, at the time of, or at any time during the 12 month period immediately prior
to, Executive’s termination of employment with Nucor has been targeted by Nucor as a potential user of the products or services of Nucor or supplier of products or services to Nucor, and whom Executive or his direct reports participated in the
solicitation of or on behalf of Nucor. 
 (iv)    The term “solicit” means to initiate
contact for the purpose of promoting, marketing, selling, brokering, procuring or obtaining products or services similar to those Nucor offered or required during the tenure of Executive’s employment with Nucor or to accept business from
Customers or Suppliers or Prospective Customers or Suppliers. 

  
 7 

 (c)    Executive specifically agrees that the
post-termination obligations and restrictions in this Section 10 and in Sections 8, 9, 11, 12 and 13 will apply to Executive regardless of whether termination of employment is initiated by Nucor or Executive and regardless of the reason for
termination of Executive’s employment. Further, Executive acknowledges and agrees that Nucor’ s payments of the compensation described in Section 3, as well as any payments under the Severance Plan, are intended to compensate
Executive for the limitations on Executive’s competitive activities described in this Section 10 and Sections 11 and 12 for the Restrictive Period regardless of the reason for termination. Thus, for example, in the event that Nucor
terminates Executive’s employment without cause, Executive expressly agrees that the obligations and restrictions in this Section 10 and Sections 8, 9, 11, 12 and 13 will apply to Executive notwithstanding the reasons or motivations of
Nucor in terminating Executive’s employment. 
 11.    Nonsolicitation. Executive hereby agrees that for the
duration of Executive’s employment with Nucor, and for the Restrictive Period, Executive will NOT, either individually or through or by any agent, representative, entity, employee or otherwise, do any of the following: 

(a)    solicit, contact, or attempt to influence any Customer or Supplier to limit, curtail, cancel, or
terminate any business it transacts with, or products it receives from or supplies to Nucor; 

(b)    solicit, contact, or attempt to influence any Prospective Customer or Supplier to terminate any
business negotiations it is having with Nucor, or to otherwise not do business with Nucor; 

(c)    solicit, contact, or attempt to influence any Customer or Supplier to purchase products or services
from an entity other than Nucor or to provide products or services to an entity other than Nucor, which are the same or substantially similar to, or otherwise in competition with, those offered to the Customer or Supplier by Nucor or those offered
to Nucor by the Customer or Supplier; or 
 (d)    solicit, contact, or attempt to influence any
Prospective Customer or Supplier to purchase products or services from an entity other than Nucor or to provide products or services to an entity other than Nucor, which are the same or substantially similar to, or otherwise in competition with,
those offered to the Prospective Customer or Supplier by Nucor or those offered to Nucor by the Prospective Customer or Supplier. 

12.    Antipiracy. 

(a)    Executive agrees for the duration of the Restrictive Period, Executive will not, either individually
or through or by any agent, representative, entity, employee or otherwise, encourage, contact, or attempt to induce any employees of Nucor (i) with whom Executive had regular contact with at the time of, or at any time during the 12 month
period immediately prior to, Executive’s termination of employment with Nucor, and (ii) who are employed by Nucor at the time of the encouragement, contact or attempted inducement, to end their employment relationship with Nucor. 

(b)    Executive further agrees for the duration of the Restrictive Period not to hire for any reason any
employees described in Section 12(a) of this Agreement. 

  
 8 

 13.    Assignment of Intellectual Property Rights. 

(a)    Executive hereby assigns to Nucor Corporation Executive’s entire right, title and interest,
including copyrights and patents, in any idea, invention, design of a useful article (whether the design is ornamental or otherwise), work product and any other work of authorship (collectively the “Developments”), made or conceived
solely or jointly by Executive at any time during Executive’s employment by Nucor (whether prior or subsequent to the execution of this Agreement), or created wholly or in part by Executive, whether or not such Developments are patentable,
copyrightable or susceptible to other forms of protection, where the Developments: (i) were developed, invented, or conceived within the scope of Executive’s employment with Nucor; (ii) relate to Nucor’s actual or demonstrably
anticipated research or development; or (iii) result from any work performed by Executive on Nucor’s behalf. Executive shall disclose any Developments to Nucor’s management within 30 days following Executive’s development, making
or conception thereof. 
 (b)    The assignment requirement in Paragraph 13(a) shall not apply to an
invention that Executive developed entirely on his own time without using Nucor’s equipment, supplies, facilities or Secret Information or Confidential Information except for those inventions that (i) relate to Nucor’s business or
actual or demonstrably anticipated research or development, or (ii) result from any work performed by Executive for Nucor. 

(c)    Executive will, within 3 business days following Nucor’s request, execute a specific assignment
of title to any Developments to Nucor Corporation or its designee, and do anything else reasonably necessary to enable Nucor Corporation or its designee to secure a patent, copyright, or other form of protection for any Developments in the United
States and in any other applicable country. 
 (d)    Nothing in this Section 13 is intended to
waive, or shall be construed as waiving, any assignment of any Developments to Nucor implied by law. 

14.    Severability. It is the intention of the parties to restrict the activities of Executive only to the extent
reasonably necessary for the protection of Nucor’s legitimate interests. The parties specifically covenant and agree that should any of the provisions in this Agreement be deemed by a court of competent jurisdiction too broad for the protection
of Nucor’s legitimate interests, the parties authorize the court to narrow, limit or modify the restrictions herein to the extent reasonably necessary to accomplish such purpose. In the event such limiting construction is impossible, such
invalid or unenforceable provision shall be deemed severed from this Agreement and every other provision of this Agreement shall remain in full force and effect. 

15.    Enforcement. Executive understands and agrees that any breach or threatened breach by Executive of any of the
provisions of Sections 8 through 13 of this Agreement shall be considered a material breach of this Agreement, and in the event of such a breach or threatened breach of this Agreement, Nucor shall be entitled to pursue any and all of its remedies
under law or in equity arising out of such breach. If Nucor pursues either a temporary restraining order or temporary injunctive relief, then Executive agrees to expedited discovery with respect thereto and waives any requirement that Nucor post a
bond. Executive further agrees that in the event of his breach of any of the provisions of Sections 8 through 13 of this Agreement, unless otherwise prohibited by law: 

(a)    Nucor shall be entitled to (i) cancel any unexercised stock options granted under any senior
officer equity incentive compensation plan from and after the Effective Date (the “Post-Agreement Date Option Grants”), (ii) cease payment of any Monthly Amounts and any other severance payments (including those under the Severance
Plan) otherwise due hereunder, 

  
 9 

 
(iii) seek other appropriate relief, including, without limitation, repayment by Executive of any (A) Monthly Amounts already paid hereunder and (B) benefits already paid under any
severance plan (including the Severance Plan) or similar benefit plans; and 
 (b)    Executive shall
(i) forfeit any (A) unexercised Post-Agreement Date Option Grants and (B) any shares of restricted stock or restricted stock units granted under any senior officer equity incentive compensation plan that vested during the six
(6) month period immediately preceding Executive’s termination of employment (the “Vested Stock”) and (ii) forfeit and immediately return upon demand by Nucor any profit realized by Executive from the exercise of
any Post-Agreement Date Option Grants or sale or exchange of any Vested Stock during the six (6) month period preceding Executive’s breach of any of the provisions of Sections 8 through 13 of this Agreement. 

Executive agrees that any breach or threatened breach of any of the provisions of Sections 8 through 13 will cause Nucor irreparable harm which cannot be
remedied through monetary damages and the alternative relief set forth in Sections 15(a) and (b) shall not be considered an adequate remedy for the harm Nucor would incur. Executive further agrees that such remedies in Sections 15(a) and
(b) will not preclude injunctive relief. 
 If Executive breaches or threatens to breach any of the provisions of Sections 10, 11 or 12 of this
Agreement and Nucor obtains an injunction, preliminary or otherwise, ordering Executive to adhere to the Restrictive Period required by the applicable Section, then the applicable Restrictive Period will be extended by the number of days that Nucor
has alleged that Executive has been in breach of any of these provisions. 
 Executive further agrees, unless otherwise prohibited by law, to pay
Nucor’s attorneys’ fees and costs incurred in successfully enforcing its rights pursuant to this Section 15, or in defending against any action brought by Executive or on Executive’s behalf in violation of or under this
Section 15 in which Nucor prevails. Executive agrees that Nucor’s actions pursuant to this Section 15, including, without limitation, filing a legal action, are permissible and are not and will not be considered by Executive to be
retaliatory. Executive further represents and acknowledges that in the event of the termination of Executive’s employment for any reason, Executive’s experience and capabilities are such that Executive can obtain employment and that
enforcement of this Agreement by way of injunction will not prevent Executive from earning a livelihood. 

16.    Reasonableness of Restrictions. Executive has carefully considered the nature and extent of the restrictions
upon him and the rights and remedies conferred upon Nucor under Sections 8, 9, 10, 11, 12, 13 and 15 and hereby acknowledges and agrees that the same are reasonable in time and territory, are designed to eliminate competition which would otherwise
be unfair to Nucor, do not interfere with Executive’s exercise of his inherent skill and experience, are reasonably required to protect the legitimate interests of Nucor, and do not confer a benefit upon Nucor disproportionate to the detriment
to Executive. Executive certifies that he has had the opportunity to discuss this Agreement with such legal advisors as he chooses and that he understands its provisions and has entered into this Agreement freely and voluntarily. 

17.    Applicable Law. Following Executive’s promotion to Executive Vice President of Nucor Corporation,
Executive’s primary place of employment will be Nucor’s corporate headquarters located in Charlotte, North Carolina. Accordingly, this Agreement is made in, and shall be interpreted, construed and governed according to the laws of, the
State of North Carolina, regardless of choice of law principles of any jurisdiction to the contrary. Each party, for themselves and their successors and assigns, hereby irrevocably (a) consents to the exclusive jurisdiction of the North
Carolina state and federal courts located 

  
 10 

 
in Mecklenburg County, North Carolina and (b) waives any objection to any such action based on venue or forum non conveniens. Further, Executive hereby irrevocably consents to the
jurisdiction of any court or similar body within the Restricted Territory for enforcement of any judgment entered in a court or similar body pursuant to this Agreement. This Agreement is intended, among other things, to supplement the provisions of
the North Carolina Trade Secrets Protection Act and the Defend Trade Secrets Act of 2016, each as amended from time to time, and the duties Executive owes to Nucor under North Carolina common law, including, but not limited to, the duty of loyalty.

 18.    Executive to Return Property. Executive agrees that upon (a) the termination of Executive’s
employment with Nucor and within three (3) business days thereof, whether by Executive or Nucor for any reason (with or without cause), or (b) the written request of Nucor, Executive (or in the event of the death or disability of
Executive, Executive’s heirs, successors, assigns and legal representatives) shall return to Nucor any and all property of Nucor regardless of the medium in which such property is stored or kept, including but not limited to all Secret
Information, Confidential Information, notes, data, tapes, computers, lists, customer lists, names of customers, reference items, phones, documents, sketches, drawings, software, product samples, rolodex cards, forms, manuals, keys, pass or access
cards and equipment, without retaining any copies or summaries of such property.    Executive further agrees that to the extent Secret Information or Confidential Information are in electronic format and in Executive’s
possession, custody or control, Executive will provide all such copies to Nucor and will not keep copies in such format but, upon Nucor’s request, will confirm the permanent deletion or other destruction thereof. 

19.    Entire Agreement; Amendments. This Agreement discharges and cancels all previous agreements regarding
Executive’s employment with Nucor, including without limitation that certain Executive Agreement by and between Nucor Corporation and Executive dated as of December 15, 2011, and constitutes the entire agreement between the parties with
regard to the subject matter hereof. No agreements, representations, or statements of any party not contained herein shall be binding on either party. Further, no amendment or variation of the terms or conditions of this Agreement shall be valid
unless in writing and signed by both parties. 
 20.    Assignability. This Agreement and the rights and duties
created hereunder shall not be assignable or delegable by Executive. Nucor may, at its option and without consent of Executive, assign its rights and duties hereunder to any successor entity or transferee of Nucor Corporation’s assets. 

21.    Binding Effect. This Agreement shall be binding upon and inure to the benefit of Nucor and Executive and
their respective successors, assigns, heirs and legal representatives. 
 22.    No Waiver. No failure or delay by
any party to this Agreement to enforce any right specified in this Agreement will operate as a waiver of such right, nor will any single or partial exercise of a right preclude any further or later enforcement of the right within the period of the
applicable statute of limitations. No waiver of any provision hereof shall be effective unless such waiver is set forth in a written instrument executed by the party waiving compliance. 

23.    Cooperation. Executive agrees that both during and after his employment, he shall, at Nucor’s request,
render all assistance and perform all lawful acts that Nucor considers necessary or advisable in connection with any litigation involving Nucor or any of its directors, officers, employees, shareholders, agents, representatives, consultants,
clients, customers, suppliers or vendors. Executive understands and agrees that Nucor will reimburse him for any reasonable documented expense he incurs related to this cooperation and assistance, but will not be obligated to pay him any additional
amounts. 
 24.    Compliance with Code Section 409A. Notwithstanding anything in this
Agreement to 

  
 11 

 
the contrary, if (a) Executive is a “specified employee” under Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986 (the “Code”) as of the date of
his separation from service and (b) any amount or benefit that Nucor determines would constitute non-exempt “deferred compensation” for purposes of Section 409A of the Code would otherwise
be payable or distributable under this Agreement by reason of Executive’s separation from service, then to the extent necessary to comply with Code Section 409A: (i) if the payment or distribution is payable in a lump sum,
Executive’s right to receive payment or distribution of such non-exempt deferred compensation will be delayed until the earlier of Executive’s death or the seventh month following Executive’s
separation from service, and (ii) if the payment, distribution or benefit is payable or provided over time, the amount of such non-exempt deferred compensation or benefit that would otherwise be payable
or provided during the six (6) month period immediately following Executive’s separation from service will be accumulated, and Executive’s right to receive payment or distribution of such accumulated amount or benefit will be delayed
until the earlier of Executive’s death or the seventh month following Executive’s separation from service and paid or provided on the earlier of such dates, without interest, and the normal payment or distribution schedule for any
remaining payments, distributions or benefits will commence. 
 For purposes of this Agreement, the term “separation from service”
shall be defined as provided in Code Section 409A and applicable regulations, and Executive shall be a “specified employee” during the twelve (12) month period beginning April 1 each year if Executive met the requirements of
Section 416(i)(1)(A)(i), (ii) or (iii) of the Code (applied in accordance with the regulations thereunder and disregarding Section 416(i)(5) of the Code) at any time during the twelve (12) month period ending on the
December 31 immediately preceding his separation from service. 
 [Signatures Appear on Following Page] 

  
 12 

 IN WITNESS WHEREOF, Executive and Nucor Corporation have executed this Agreement to be effective
as of the Effective Date.EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(c) and 240.24b-2 

EXECUTION VERSION 

CONFIDENTIAL SETTLEMENT AND LICENSE AGREEMENT 

This Confidential Settlement And License Agreement (the “Settlement Agreement”) is entered into by and among HORIZON
THERAPEUTICS, LLC, a corporation organized and existing under the laws of the State of Delaware with a principal place of business at 150 S. Saunders Road, Lake Forest, Illinois, 60045 (“Plaintiff”) and LUPIN LTD., a corporation
organized and existing under the laws of India with a principal place of business at Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai 400055, India (“Lupin Ltd.”) and LUPIN PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of the State of Delaware with a principal place of business at 111 South Calvert Street, Harborplace Tower 21st Floor, Baltimore, MD 21202 (“LPI”) (collectively with Lupin Ltd.,
“Lupin”) (each individually a “Party”, collectively, the “Parties”), and made effective as of the date upon final execution of the Settlement Agreement by an authorized representative of each Party (the “Effective
Date”). 
 WHEREAS Horizon Therapeutics, LLC is the owner of approved New Drug Application (“NDA”) No. 203284 for
RAVICTI® (glycerol phenylbutyrate) Oral Liquid, 1.1 gm/mL; 
 WHEREAS Horizon
Therapeutics, LLC is the owner of U.S. Patent Nos. 8,404,215 (“the ‘215 patent”), 8,642,012 (“the ‘012 patent”), 9,095,559 (“the ‘559 patent”), 9,254,278 (“the ‘278 patent”), 9,326,966
(“the ‘966 patent”), and 9,561,197 (“the ‘197 patent”) (collectively, “the RAVICTI® Patents”), and Plaintiff represents that they hold all substantial
rights to the RAVICTI® Patents; 

  

			
	Confidential Settlement Agreement	  	Page 1 of 36

 EXECUTION VERSION 

 

 WHEREAS Lupin Ltd., is the owner of ANDA No. 207694 for generic glycerol phenylbutyrate
oral liquid, 1.1 gm/mL; 
 WHEREAS Plaintiff filed lawsuits against Lupin in the United States District Court for the District of New
Jersey, C.A. Nos. 15-cv-7624-RBK-JS, 16-cv-4438-RBK-JS, and 17-cv-5900-KM-MAH (alleging that the filing of ANDA No. 207694 infringes the ‘215, ‘012, ‘559, ‘278, ‘966, and’197 patents) (the “Lawsuits”);

 WHEREAS Lupin filed petitions for Inter Partes Review with the Patent Trial and Appeal Board (“PTAB”) seeking a finding of
invalidity of ‘559 patent (Case No. IPR2016-00829), the ‘278 patent (Case No. IPR2017-01159), the ‘966 patent (Case No. IPR2017-01160) and the ‘197 patent (Case No. IPR2018-00459) (the “IPRs”); 

WHERAS the PTAB found the ‘559 patent to be unpatentable, which decision Plaintiff has appealed to the Court of Appeals for the
Federal Circuit, Appeal No. 18-1225 (the “Appeal”); 
 WHEREAS the Parties wish to
avoid the significant legal expense and legal risks involved in continuing the Lawsuits, the IPRs and the Appeal by settling the Lawsuits, the IPRs and the Appeal on the terms and conditions set forth in this Settlement Agreement; and 

WHEREAS as a result of this Settlement Agreement there may be additional supply and sales in the Territory of the generic form of RAVICTI® for human use in advance of the expiration of the RAVICTI® Patents, which supply and sales otherwise may not have been made until after
the expiration of those patents. 
 NOW, THEREFORE, in consideration of the mutual execution of this Settlement Agreement and the
promises made herein, the Parties agree as follows: 

  

			
	Confidential Settlement Agreement	  	Page 2 of 36

 EXECUTION VERSION 

 

 1. Definitions. 

a) “Affiliate” of a Party means any person or entity that controls, is controlled by or is under common control with such
Party. As used in this definition, “control” of an entity means: (a) in the case of a corporate entity, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election
of directors of such entity; and (b) in the case of a non-corporate entity, the direct or indirect power to either: (i) direct the management and policies of
thenon-corporate entity; or (ii) elect at least fifty percent (50%) of the members of the governing body of such non-corporate entity. 

b) “ANDA” means an abbreviated new drug application (or equivalent regulatory mechanism, including an application under
21 U.S.C. § 355(b)(2)). 
 c) “Applicable Law” means all applicable provisions of constitutions, statutes, rules,
regulations, ordinances and orders of all Governmental Entities and all orders and decrees of all courts, tribunals and arbitrators. 
 d)
“Authorized Generic” means a generic version of the NDA Product that is Marketed or intended for Marketing in the Territory, other than by Plaintiff or their Affiliates, under the
RAVICTI® NDA without the RAVICTI® trademark (or any replacement trademark). 

e) “Cost of Authorized Generic” means the actual cost of goods sold for the Authorized Generic determined in accordance with
U.S. GAAP and in accordance 

  

			
	Confidential Settlement Agreement	  	Page 3 of 36

 EXECUTION VERSION 

 

 
with Plaintiffs’ normal and standard accounting practices for RAVICTI® and its other pharmaceutical products. 

f) “FDA” means the United States Food and Drug Administration and any successor agency having the same functions. 

g) “Final Decision” means a decision by a court or the U.S. Patent Trial and Appeal Board that is no longer subject to a right
of appeal (other than by a petition to the United States Supreme Court for a writ of certiorari). 
 h) “First
Applicant” shall have the meaning set forth in 21 U.S.C. § 355G)(5)(B)(iv)(II) (as amended or replaced). 
 i) “Generic
Product” means a pharmaceutical product which has been approved by or submitted for approval to FDA under an ANDA or NDA (pursuant to 21 U.S.C. § 355(b)(2)) (as amended or replaced), other than by Plaintiff or their
Affiliates, as a generic version of RAVICTI®. 
 j) “Governmental
Entity” means any (i) nation, state, county, city, town, village, district, or other jurisdiction of any nature, (ii) federal, state, local, municipal, foreign, or other government, (iii) governmental or
quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), (iv) multi-national organization or body, or (v) body exercising, or entitled to
exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature. 

  

			
	Confidential Settlement Agreement	  	Page 4 of 36

 EXECUTION VERSION 

 

	 	k)	 “Gross Profit” means the gross invoice price of sales of the Authorized Generic in the
Territory by Lupin and its Affiliates to Third Parties, recorded in accordance with U.S. GAAP, less the following reasonable and customary deductions from such gross amounts (but only if and to the extent relating to the Authorized Generic, as
accrued): 

  

	 	(i)	 Cost of Authorized Generic; 

 

	 	(ii)	 customary and commercially reasonable allowances for returns and discounts, including, without limitation,
credits for unsold or shortdated Authorized Generic product, customer program accruals (overbills, administrative fees, third party rebates, sales brokerage, and volume rebates), allowances granted in the invoice, cash discounts, discounts made by
means of floor stock adjustments, rebates or charge-backs directly related to sales of the Authorized Generic (and including rebates or other payments required to be paid to government entities in connection with sales of the Authorized Generic
pursuant to the Omnibus Budget Reconciliation Act of 1990 and similar or other Federal or state legislation or programs); 

  

	 	(iii)	 taxes, duties or other governmental charges to the extent actually included in the gross invoice price;

  

	 	(iv)	 actual and/or accrued distribution and shipping costs, including but not limited to distribution service fees
and other customary charges 

  

			
	Confidential Settlement Agreement	  	Page 5 of 36

 EXECUTION VERSION 

 

	 	
incurred in accordance with wholesaler and third party logistics agreements, such as warehousing and shipping agreements; and 

 

	 	(v)	 any receivables which have been included in gross sales in the books of Lupin and are deemed to be
uncollectible according to Lupin’s internal accounting principles and U.S. GAAP consistently applied. Such bad debt deduction shall be applied to New Sales in the period in which such receivables are written off and shall be exclusive of any
bad debt or uncollectible receivables of Lupin unrelated to any Authorized Generic product. 

 l) “Licensed
Patents” means the RAVICTI® Patents, and any extensions, divisionals, continuations,
continuations-in-part, reissues, reexaminations, inter partes reviews, amendments thereto, and post-grant reviews thereof, and any foreign counterparts or
equivalents thereof (regardless of whether any claim of priority is asserted or otherwise exists), and any other patents prospectively listed in the Orange Book for the NDA Product. 

m) “Lupin ANDA” means ANDA No. 207694 for glycerol phenylbutyrate oral liquid, 1.1 gm/mL as it exists as of the Effective
Date, including any future supplements, amendments and/or modifications to the ANDA that were made to gain approval from the FDA, provided such supplements, amendments and/or modifications do not change the active ingredient, dosage form,
reference listed 

  

			
	Confidential Settlement Agreement	  	Page 6 of 36

 EXECUTION VERSION 

 

 
drug, or AB rating of any generic product described in the ANDA as it exists as of the Effective Date. 

n) “Lupin Generic Product” means the glycerol phenylbutyrate oral liquid, 1.1 gm/mL product described in the Lupin ANDA. 

o) “Manufacture” means to use, make or have made a product. 

 

	 	p)	 “Market” and “Marketing” means to offer for sale, sell, or distribute
aproduct. 

  

	 	q)	 “NDA” means a new drug application (or equivalent regulatorymechanism). 

 

	 	r)	 “NDA Product” or
“RAVICTI®” means the glycerol phenylbutyrate oral liquid product approved under the RAVICTI® NDA, including any
amendments and supplements thereto. 

  

	 	s)	 “Officially Discontinue” means any of: (a) delisting the NDA Product with the FDA;
(b) delisting or removing all Licensed Patents, or the NDA Product, from the FDA’s Orange Book; (c) seeking or otherwise undertaking any action with the FDA to withdraw the NDA Product from the market; and/or (d) deleting,
removing, designating as “obsolete” or canceling any National Drug Code(s) or any other relevant code(s) for the NDA Product from the applicable National Drug Data File maintained by First Databank (or any successor or equivalent
organization), or from any other pricing database. 

  

			
	Confidential Settlement Agreement	  	Page 7 of 36

 EXECUTION VERSION 

 

	 	t)	 “Orange Book” means the FDA’s publication “Approved Drug Products With Therapeutic
Equivalence Evaluations.” 

  

	 	u)	 “Original Generic” means a generic version of the NDA Product that is Marketed or intended for
Marketing in the Territory, by Plaintiff or their Affiliates, under the RAVICTI® NDA without the RAVICTI® trademark (or any replacement
trademark). 

  

	 	v)	 “RAVICTI® NDA” means
NDA No. 203284, including any amendments or supplements thereto (including without limitation any amendments or supplements adding additional dosage strengths, indications, dosing regimens or other clinical data or information).

  

	 	w)	 “Territory” means the United States of America and its territories, commonwealths and
possessions, including without limitation, the Commonwealth of Puerto Rico and the District of Columbia. 

  

	 	x)	 “Third Party” means any person or entity other than the Parties and their respective
Affiliates. 

 2. Final Dismissal of Litigations. Within [...***...] business days of [...***...], the
Parties shall enter into and cause to be filed in the Lawsuits a Stipulated Order of Dismissal and [Proposed] Order in the forms attached as Exhibits A and B to this Settlement Agreement, shall enter into and cause to be filed in the IPRs a
joint request for termination pursuant to 35 U.S.C. § 317 together with a copy of the Settlement Agreement as required (“Joint Request”), and Lupin shall withdraw from and no longer participate in the Appeal

  

			
	Confidential Settlement Agreement	  	Page 8 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
and shall cause to be filed in the Appeal a Motion to Withdraw in the form attached as Exhibit C, pursuant to which all claims in the Lawsuits will be dismissed and the IPRs will be terminated at
the discretion of the PTAB without costs or fees, [...***...]. 
 3. Agreement Not to Challenge Validity or
Enforceability. Lupin agrees not to seek review of or contest, in any United States forum (e.g., U.S. courts, ITC, U.S. Patent and Trademark Office (e. g., Inter Partes Review, Reexamination, Interference)), the validity or enforceability of
the Licensed Patents nor take any action intended to adversely affect Plaintiff’s rights in and to the Licensed Patents. For the avoidance of doubt, the foregoing shall not preclude Lupin from contesting, in any forum (e.g., U.S.
courts, ITC, U.S. Patent and Trademark Office (e.g., Inter Partes Review, Reexamination, Interference) or foreign courts or foreign patent offices), the validity or enforceability of the Licensed Patents in connection with:
(1) any other ANDA or NDA filed by, for or on behalf of Lupin that is not the Lupin ANDA and that references a drug product other than RAVICTI® for which the Licensed Patents are listed
in the Orange Book, and (2) any foreign regulatory submission by, for or on behalf of Lupin. For the avoidance of doubt, the foregoing shall not preclude Lupin from filing and/or maintaining in the Lupin ANDA any certifications under 21
U.S.C. § 355G)(2)(A)(vii)(IV) (as amended or replaced) to any Licensed Patents or any patents listed in the Orange Book in connection with the RAVICTI® NDA. 

4. Releases. 
 a)
Plaintiff’s Release. Plaintiff, for themselves and their Affiliates, agents, successors and assigns, does hereby forever release and discharge Lupin, and any of its past or present agents, employees, officers, directors,
and suppliers, and any 

  

			
	Confidential Settlement Agreement	  	Page 9 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
past or present distributors, resellers, purchasers and/or end-users of products sold or distributed by Lupin, from any causes of action, losses,
promises, damages, costs, expenses, liabilities and/or demands of whatsoever character, nature and kind, known or unknown, suspected or unsuspected, fixed or contingent, arising out of or in any way related to the Lupin Generic Product or
the actions, conduct, omissions, or events alleged, or which could have been alleged, in the Lawsuits, the IPRs and the Appeal. 
 b)
Lupin’s Release. Lupin, for itself and its Affiliates, agents, successors and assigns, does hereby forever release and discharge Plaintiff, and any of their past or present agents, employees, officers, directors, and suppliers, and
any past or present distributors, resellers, purchasers and/or end-users of products sold or distributed by Plaintiff from any causes of action, losses, promises, damages, costs, expenses, liabilities
and/or demands of whatsoever character, nature and kind, known or unknown, suspected or unsuspected, fixed or contingent, arising out of or in any way related to the Lupin Generic Product or the actions, conduct, omissions, or
events alleged, or which could have been alleged, in the Lawsuits, the IPRs and the Appeal. 
 5. License, Waiver and Covenant

 a) Plaintiff hereby grants Lupin a non-exclusive, perpetual, royalty-free license under the
Licensed Patents to make, have made, use, import, sell and offer 

  

			
	Confidential Settlement Agreement	  	Page 10 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
for sale in the Territory the Lupin Generic Product on and after the License Effective Date. 

b) Plaintiff hereby grants Lupin a waiver of any regulatory exclusivities concerning
RAVICTI® to which Plaintiff may be entitled and that may prevent approval of the Lupin ANDA on or after the License Effective Date, and within [...***...] business days of Lupin’s
request, Plaintiff shall submit, and/or shall cause its Affiliates to submit, appropriate and reasonable documentation to the FDA (in a form acceptable to FDA, together with any other necessary submissions, all subject to review
by Lupin prior to submission) evidencing the licenses, covenant not to sue, and waivers set forth in this Agreement. 
 c) Plaintiff and
their Affiliates, on and after the License Effective Date (or earlier, limited solely to the activities provided in Section 7 of this Settlement Agreement), hereby covenant not to sue Lupin and its Affiliates, and their
importers, suppliers, distributors, and customers, or support or encourage any Third Party to sue, for infringement of any United States or foreign patents owned, licensed or otherwise controlled, wholly or in part, by Plaintiff and/or any
of their Affiliates purporting to cover the Lupin Generic Product and/or the making, using, selling, or offering for sale in the Territory, or making or having made only for importation, use, sale or offering for sale into or for the Territory of
the Lupin Generic Product. For the Licensed Patents, the foregoing covenant not to sue shall hereby be treated as a non-exclusive license to such patents for the Lupin Generic

  

			
	Confidential Settlement Agreement	  	Page 11 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
Product solely for the purpose of allowing Lupin and/or its Affiliates to file and maintain with the FDA a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or
replaced) with respect thereto. Lupin shall have the right to maintain its existing certifications under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or replaced) against the Licensed Patents. Lupin also shall have the right to file
a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or replaced) in connection with the Lupin Generic Product against any Licensed Patents, and still be covered by the covenant not to sue. 

d) Upon written request by Lupin, made no earlier than [...***...] days prior to the License Effective Date, Plaintiff will notify
Lupin in writing of all the then required labeling information for the NDA Product as reasonably requested. 
 6. License Effective
Date. The License Effective Date for the Lupin Generic Product will be the earliest to occur of: 
 a) July 1, 2026; or 

b) The entry of a Final Decision holding that all of the then-asserted claims of the Licensed Patents excluding foreign counterparts or
foreign equivalents thereof against a Generic Product are unenforceable, invalid, or not infringed; or 
 c) The date on which the latest
expiring of the Licensed Patents excluding foreign counterparts or foreign equivalents thereof, that has not been found invalid or unenforceable by a Final Decision, has expired, been permanently abandoned, or delisted from the Orange
Book; or 

  

			
	Confidential Settlement Agreement	  	Page 12 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 d) [...***...] 

e) The date on which a Generic Product is first sold in the Territory after the Effective Date by a Third Party other than by Lupin or a First
Applicant, but only if the sale of the Generic Product has been authorized or licensed by Plaintiff (directly or indirectly, by way of license, covenant not to sue, release, or otherwise); or 

f) [...***...] business days after the date on which Plaintiff receives notice that a Generic Product is first sold in the Territory
without authorization from Plaintiff or its Affiliates (by license, sublicense, covenant not to sue or otherwise) (“Unauthorized Third Party Launch”) after the Effective Date, unless within [...***...] business days from
receiving such notice (a) Plaintiff moves for a temporary restraining order or preliminary injunction prohibiting any further sale of such Generic Product within the Territory, or (b) Plaintiff enters into an agreement with
the Third Party selling such Generic Product to cease and desist from the sale of a Generic Product. If Plaintiff does seek a temporary restraining order or preliminary injunction within such [...***...] business day period, the License
Effective Date will be deemed to have occurred on the earlier of (X) the date that the application for a temporary restraining order or preliminary injunction is first denied, abandoned or 

  

			
	Confidential Settlement Agreement	  	Page 13 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
withdrawn (with Lupin’s license to remain effective without regard to later action, judicial or otherwise, on the application), and (Y) [...***...] calendar days after the application
for a restraining order or preliminary injunction is filed unless a temporary restraining order or preliminary injunction is issued against the Third Party seeking to sell the unauthorized Generic Product before [...***...] calendar
days after such application (with the understanding that a subsequent re-introduction of such Generic Product or an introduction of a different Generic Product may give rise to the occurrence of
a License Effective Date consistent with this Agreement). 
 7. Pre-Commercial /Pre-Marketing License. Plaintiff grants to Lupin a limited pre- commercialization and pre-marketing license as follows: 

a) up to [...***...] days prior to the License Effective Date, Lupin shall have the right to Manufacture and/or have
Manufactured the Lupin Generic Product in or for, and/or import or have imported the Lupin Generic Product into, the Territory to enable Lupin to Market the Lupin Generic Product in the Territory on or after the License Effective
Date; 
 b) up to [...***...] days prior to the License Effective Date, Lupin shall have the right to notify potential
customers of the upcoming availability of Lupin Generic Product; 

  

			
	Confidential Settlement Agreement	  	Page 14 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 c) up to [...***...] days prior to the License Effective Date, Lupin shall have the
right to provide non-binding offers to potential customers for the sale of the Lupin Generic Product; and 

d) up to [...***...] days prior to the License Effective Date, Lupin shall have the right to enter into binding contracts with
customers for the sale of Lupin Generic Product. 
 8. Authorized Generic. 

(a) Lupin shall be the exclusive distributor of an Authorized Generic supplied by Plaintiff for a [...***...] day period following
[...***...], and Plaintiff shall not sell an Original Generic during such [...***...]-day period. [...***...] For sales made by Lupin of Authorized Generic product during this period,
Plaintiff shall receive [...***...] and Lupin shall retain [...***...]. Each payment by Lupin to Plaintiff shall be made in U.S. dollars within [...***...] calendar days of the end of the Lupin Fiscal Quarter to which such
payment relates. 
 (b) Upon expiration of such [...***...]-day period described in
Section 8(a), Lupin shall be the non-exclusive distributor of an Authorized Generic supplied by Plaintiff if, and only if, Lupin does not have approval for the Lupin ANDA or Lupin has approval for
the Lupin ANDA but is unable, despite using commercially reasonable efforts, to manufacture or release Lupin Generic Product for sale. For sales of Authorized Generic product made by Lupin pursuant to this provision, Plaintiff

  

			
	Confidential Settlement Agreement	  	Page 15 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
shall receive [...***...] and Lupin shall retain [...***...]. Any payment by Lupin to Plaintiff made pursuant to this provision shall be made in U.S. dollars within
[...***...] calendar days of the end of the Lupin Fiscal Quarter to which such payment relates. Once Lupin has approval for the Lupin ANDA and is able to manufacture and release Lupin Generic Product for sale to Third Parties, its rights under
this Section 8(b) shall be terminated. 
 (c) The parties will enter into a formal supply agreement (“Supply Agreement”) to
memorialize the details of Plaintiff’s supply of and Lupin’s distribution of the Authorized Generic. The Supply Agreement will, in addition to the preceding “key terms,” contain commercially reasonable terms and conditions. The
Supply Agreement will be entered into within [...***...] months of the Effective Date unless extended by mutual agreement. In the event the parties cannot agree to any of the other terms of the Supply Agreement, the “key terms”
in this Section 8 shall be binding and not negotiable and the parties shall utilize binding arbitration or mediation to resolve any terms in dispute. 

9. Non-Interference. From and after the Effective Date, unless required by the FDA
for reasons of safety or efficacy, Plaintiff shall not (a) file any citizen petition or other regulatory submissions with the FDA or any other governmental agency or take any other action that would interfere with Lupin’s efforts to:
(i) obtain FDA approval of the Lupin ANDA; or (ii) Market the Lupin Generic Product as of the date and under the terms provided in this Settlement Agreement; or (b) Officially Discontinue the NDA Product prior to expiration of the
Licensed Patents. 

  

			
	Confidential Settlement Agreement	  	Page 16 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 10. Most Favored Nation. In the event that Plaintiff, or any of their Affiliates, has
entered into or enters into after the Effective Date any agreement, license, sublicense, settlement, covenant, waiver, or other authorization of any kind with any Third Party: (i) for a Generic Product other than a First Applicant,
granting such Third Party a license or other authorization under the Licensed Patents containing a License Effective Date, pre-commercialization terms, pre-marketing
terms more favorable than those provided to Lupin herein, or (ii) for an Authorized Generic [...***...], Plaintiff will immediately give Lupin notice of such agreement (and in no event less than [...***...] business days after
entering into such agreement) and this Agreement shall be automatically amended to include such more favorable terms accordingly. 

11. Entire Agreement. This Settlement Agreement constitutes the complete agreement of the Parties with respect to the subject
matter hereof and supersedes and replaces any prior negotiations, mediations, proposed agreements or agreements, whether written or oral. This Settlement Agreement may be modified only by a writing signed by all Parties. 

12. Successors and Assigns. Neither this Settlement Agreement nor any of the rights or obligations hereunder may be assigned,
transferred, licensed, sub-licensed or delegated by either Party, without the prior written consent of the other Party, such consent not to be unreasonably withheld, except to an Affiliate of the assigning
Party or to the successor to all or substantially all of the business or assets of such Party to which this Settlement Agreement relates (whether by merger, sale of stock, sale of assets or other transaction) that agrees in writing to be
bound by the terms and conditions of this Agreement. Any permitted successor or assignee of rights and/or 

  

			
	Confidential Settlement Agreement	  	Page 17 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
obligations hereunder shall, in a writing to the other Parties, expressly assume performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the
assigning Party. Any assignment or attempted assignment by any Party in violation of the terms of this paragraph shall be null and void. 

13. Confidential Information. 

a) Treatment of Confidential Information. During the term of this Settlement Agreement and continuing thereafter, each Party shall keep
confidential and not disclose to others or use for any purpose, other than as authorized by this Settlement Agreement, all Confidential Information which was provided to it by any other Party or its Affiliates or their respective employees or
representatives pursuant to this Settlement Agreement. For purposes of this Settlement Agreement, the term “Confidential Information” means the terms of this Settlement Agreement and any information furnished in connection with this
Settlement Agreement, including without limitation any and all know-how, trade secrets, formulae, data, inventions, technology and other information, including manufacturing techniques, processes, trade and
financial information, related to the manufacture, use, sale or marketing of any products that are the subject of this Settlement Agreement, currently in the possession of, or developed during the term of the Settlement Agreement by Lupin,
Plaintiff or any of their respective Affiliates. The restrictions of this Section shall not apply to any Confidential Information which (i) is already known to the recipient at the time of disclosure, as reasonably documented by
written records; 

  

			
	Confidential Settlement Agreement	  	Page 18 of 36

 EXECUTION VERSION 

 

 
(ii) is or later becomes public knowledge through no fault of the recipient; (iii) is received from a Third Party having the lawful right to disclose the information; or (iv) is
independently developed by employees of the recipient without access to the disclosing Party’s Confidential Information. 
 b)
Permitted Disclosure. A Party may disclose Confidential Information of another Party to (i) its Affiliates, and to its and their directors, employees, consultants, attorneys, and agents, in each case who have a specific need to know
such Confidential Information and who are bound by a like obligation of confidentiality and restriction on use; (ii) any bona fide actual or prospective collaborators, underwriters, investors, lenders or other financing sources who are
obligated to keep such information confidential, to the extent reasonably necessary to enable such actual or prospective collaborators, underwriters, investors, lenders or other financing sources to determine their interest in
collaborating with, underwriting or making an investment in, or otherwise providing financing to, the receiving Party; and (iii) the extent such disclosure is required to comply with Applicable Law or to defend or prosecute litigation,
provided, however, that the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes reasonable and lawful actions to avoid or minimize the degree of such disclosure, including upon the disclosing
Party’s request, seeking confidential treatment of such Confidential Information. If a Governmental Entity directs or recommends to Lupin that Lupin transfer the Lupin ANDA to a Third Party, Lupin

  

			
	Confidential Settlement Agreement	  	Page 19 of 36

 EXECUTION VERSION 

 

 
may disclose a copy of this Settlement Agreement to a Third Party in connection with such a possible transfer so long as the Third Party agrees to confidential treatment of this
Settlement Agreement. 
 c) Return of Confidential Information. This Settlement Agreement does not constitute the conveyance of
ownership with respect to or a license to any Confidential Information, except as otherwise provided in this Settlement Agreement. Upon the expiration or termination of this Settlement Agreement for any reason, each Party agrees,
except as otherwise provided in this Settlement Agreement, to return to the other Party or destroy (and certify such destruction) all documentation or other tangible evidence or embodiment of Confidential Information belonging to the other
Party and not to use same, unless otherwise agreed in writing. The Parties agree and acknowledge that the foregoing obligation does not apply to Confidential Information recorded on electronic back-up
tapes that are maintained in the ordinary course and are unreasonably difficult to access. 
 d) Publicity. No public
announcement or other disclosure to Third Parties concerning the existence or terms of this Settlement Agreement shall be made, either directly or indirectly, by any Party, without first obtaining the written approval of the other Parties
and agreement upon the nature, text and timing of such announcement or disclosure, such approval and agreement not to be unreasonably withheld; provided, however, that any Party shall have the right to make any such public announcement or other
disclosure required by Applicable Law after such 

  

			
	Confidential Settlement Agreement	  	Page 20 of 36

 EXECUTION VERSION 

 

 
Party has provided to the other Party a copy of such announcement or disclosure and a reasonable opportunity to comment thereon; and provided that Lupin shall
have the right to inform its customers that Lupin has obtained a license to sell a Generic Product and an Authorized Generic in the Territory. Notwithstanding the above, either party may, without the permission of the other party,
issue a press release disclosing that the litigation has settled. Lupin agrees that any customer notification will not be provided more than [...***...] days prior to the Licensed Effective Date. Each Party agrees that it shall cooperate
fully with the other Parties with respect to all disclosures regarding this Settlement Agreement to any governmental or regulatory agencies, including requests for confidential treatment of proprietary information of any Party included in
any such disclosure. 
 e) Disclosure to Government or in Discovery. Specific terms or conditions of this Settlement Agreement
may be disclosed pursuant to a discovery demand; subpoena; order of a court, administrative body or arbitrator; or administrative guidance that in the opinion of a Party’s counsel requires disclosure. If a Party receives a request to
disclose any of the terms or conditions of this Settlement Agreement pursuant to a discovery demand; subpoena; order of a court, administrative body or arbitrator; or administrative guidance that in the opinion of such Party’s counsel
requests disclosure, such Party shall notify the other Parties within [...***...] days after receiving such request and at least [...***...] days prior to disclosing any terms of this Settlement Agreement. Such Party may then

  

			
	Confidential Settlement Agreement	  	Page 21 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 
disclose the terms and conditions of this Settlement Agreement pursuant to such request, provided that it shall have used reasonable efforts to ensure that such disclosure is subject to
a protective order limiting access to the disclosure to outside counsel and expert witnesses of the entity receiving the Confidential Information. Nothing herein shall preclude any Party from complying with an order requiring disclosure, or a
guidance that in the opinion of such Party’s counsel requires disclosure, of the terms of this Settlement Agreement that has been issued by a court, arbitrator or administrative agency of competent jurisdiction. Nothing herein shall
prohibit the Parties from disclosing this Settlement Agreement and its terms to the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice (“DOJ”) pursuant to the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003. 
 14. Government Review. The Parties agree to submit this Settlement Agreement to the
FTC and the DOJ as required by statute. Each Party shall, to the extent permitted by law: 
 a) promptly inform the other Parties of any
communication made or received by such Party to or from any governmental authority regarding this Settlement Agreement and/or any related agreements; and 

b) use reasonable efforts to comply with and terminate any investigation or inquiry regarding the Settlement Agreement and/or any related
agreements by any government authority, including by providing requested information to such 

  

			
	Confidential Settlement Agreement	  	Page 22 of 36

 EXECUTION VERSION 

 

 
government authority and permitting reasonable access to its documents, officials and data related to the Settlement Agreement and/or any related agreements. 

To the extent that any legal or regulatory issues or barriers arise with respect to the Settlement Agreement, or any subpart thereof, the
Parties shall work together in good faith and use reasonable efforts to modify the Settlement Agreement to overcome any such legal or regulatory issues (including, for example, objections by the FTC, the DOJ, or any applicable court) in a
mutually acceptable fashion, but in no event shall either Party be required to agree to any modification of the Settlement Agreement that materially affects the economic value of the transactions contemplated hereby. 

15. Representations and Warranties. Each Party hereby represents, warrants and covenants to the other Parties as follows: 

a) It is a limited partnership, limited liability company, company or corporation duly organized, validly existing and in good standing
under the laws of the jurisdiction in which it is incorporated or organized, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being
conducted and as contemplated in this Settlement Agreement, including, without limitation, the ability to grant the rights granted to the other Parties hereunder. 

b) As of the Effective Date: (i) it has the corporate power and authority and the legal right to have entered into, or enter into,
this Settlement Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on 

  

			
	Confidential Settlement Agreement	  	Page 23 of 36

 EXECUTION VERSION 

 

 
its part required to authorize the execution and delivery of this Settlement Agreement and the performance of its obligations hereunder; and (iii) this Settlement Agreement
has been duly executed and delivered on behalf of such Party and constitutes legal, valid and binding obligations of such Party that are enforceable against it in accordance with their terms except: (1) as limited by applicable bankruptcy;
insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally; and (2) as limited by laws relating to the availability of
specific performance, injunctive relief, or other equitable remedies. 
 c) It has not entered, and shall not enter, into any agreement with
any Third Party that is in conflict with the rights granted to the other Parties in this Settlement Agreement; it has not taken and shall not take any action that would in any way prevent it from granting the rights granted to the other
Parties under this Settlement Agreement or that would otherwise materially conflict with or adversely affect the rights granted to the other Parties under this Settlement Agreement; and its performance and execution of this Settlement Agreement does
not and will not result in a breach of any other contract to which it is a party. 
 16. Notice. Any notice required to be
delivered under or pursuant to this Settlement Agreement shall be in writing in the English language, delivered personally or sent by air mail or express courier service providing evidence of receipt, postage
pre-paid where applicable, to the following addresses of the Parties (or such other address for a Party as it specifies by like notice): 

  

			
	Confidential Settlement Agreement	  	Page 24 of 36

 EXECUTION VERSION 

 

 For Horizon Therapeutics, LLC 

Brian K. Beeler 
 Nelson Alexander

 Horizon Therapeutics, LLC 

150 S. Saunders Road 
 Lake
Forest, Illinois 60045 
 For Lupin Ltd. and Lupin Pharmaceuticals, Inc.  

Lupin Limited 
 Attention:
Managing Director 
 Kalpataru Inspire, 3rd Floor 

Off Western Express Highway 

Santacruz (East), Mumbai 400055 

India 
 Lupin Pharmaceuticals,
Inc. 
 Attention: Vice President Intellectual Property 

111 South Calvert Street 

Harborplace Tower 21st Floor 

Baltimore, MD 21202 
 with a copy
to (which will not constitute notice hereunder): 
 Knobbe, Martens, Olson & Bear, LLP 

1717 Pennsylvania Avenue, N.W., Suite 900Washington, D.C. 20006 

Attention: William R. Zimmerman 

Any notice shall be effective upon receipt by the Party to which it is addressed. 

17. No Admission/Representation Regarding Licensed Patents. Plaintiff and Lupin agree that this Agreement does not expressly or by
implication, estoppel or otherwise, constitute (a) an admission by Plaintiff as to the scope or interpretation of the claims of the Licensed Patents, nor (b) a representation or warranty that the Licensed Patents are valid and/or
enforceable. 

  

			
	Confidential Settlement Agreement	  	Page 25 of 36

 EXECUTION VERSION 

 

 18. Governing Law and Venue. This Settlement Agreement shall be governed by, and
construed in accordance with, the laws of the State of New Jersey, without regard for any conflict of law principles that would dictate the application of the laws of another jurisdiction. The Parties agree that the United States District Court
for the District of New Jersey shall have exclusive and sole jurisdiction to enforce any violation of this Settlement Agreement, except that, if for any reason that Court does not accept jurisdiction, then the state courts of New Jersey
shall have exclusive and sole jurisdiction to enforce any violation of this Settlement Agreement. The Parties hereby consent to the personal jurisdiction of those courts for any dispute arising from or relating to this Settlement
Agreement. 
 19. Severability. If any provision of this Settlement Agreement shall be held by a court of competent jurisdiction
to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and effect and the Parties shall negotiate in good faith to replace the invalid or unenforceable provision with a valid and enforceable provision that
has the effect nearest to that of the provision to be replaced. 
 20. Advice of Counsel. This Settlement Agreement has
been negotiated by the Parties and their respective counsel and shall be interpreted fairly in accordance with its terms and without any strict construction in favor of or against any Party. 

21. No Waiver. Waiver by a Party of any breach of any provision of this Settlement Agreement by another Party shall not operate or be
construed as a waiver of any subsequent or other breach. No provision of this Settlement Agreement may be waived except by a written instrument signed by the Party waiving compliance. 

  

			
	Confidential Settlement Agreement	  	Page 26 of 36

 EXECUTION VERSION 

 

 22. Regulatory Delay. No provision of this Settlement Agreement shall be affected by
any delay in the approval of the Lupin ANDA by the FDA, or the failure of Lupin to obtain FDA approval of the Lupin ANDA. 
 23.
[...***...] Expenses, and Costs and Fees. [...***...] each Party shall bear its own attorneys’ fees and costs associated with the Lawsuits, the IPRs, the Appeal, and the negotiation and preparation of this Settlement
Agreement. 
 24. Counterparts. This Settlement Agreement may be executed in one or more counterparts (including via facsimile or
electronic copy), each of which when so executed and delivered shall be deemed to be an original, but all of which taken together form but one and the same instrument. 

25. Headings. The headings and captions used in this Settlement Agreement are solely for the convenience of reference and shall
not affect its interpretation. 

  

			
	Confidential Settlement Agreement	  	Page 27 of 36
		  	***Confidential Treatment Requested

 EXECUTION VERSION 

 

 26. Interpretation and Construction. The term “including” means
“including, without limitation,” and “herein,” “hereof,” and “hereunder” refer to this Settlement Agreement as a whole. The word “will” shall be construed to have the same meaning and effect as the
word “shall.” 
 27. Bankruptcy. All licenses and rights to licenses granted under or pursuant to this Settlement Agreement
by Plaintiff to Lupin are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The
Parties agree that Lupin, as a licensee of such rights under this Settlement Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, and that upon commencement of a bankruptcy
proceeding by or against Plaintiff under the Bankruptcy Code, Lupin shall be entitled to a complete duplicate of, or complete access to (as Lupin deems appropriate), any such intellectual property and all embodiments of such intellectual
property. Such intellectual property and all embodiments thereof shall be promptly delivered to Lupin (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by Lupin, unless Plaintiff elects to continue to
perform all of its obligations under this Settlement Agreement by or on behalf of Plaintiff upon written request therefor by Lupin or (b) if not delivered under (a) above, upon the rejection of this Settlement Agreement
by or on behalf of Plaintiff upon written request therefor by Lupin. The foregoing provisions are without prejudice to any rights Lupin may have arising under the Bankruptcy Code or other applicable law. 

  

			
	Confidential Settlement Agreement	  	Page 28 of 36

 EXECUTION VERSION 

 

 IN WITNESS HEREOF, the Parties have caused their duly authorized representatives to execute
this Settlement Agreement to be effective as of the Effective Date. 
  

													
	HORIZON THERAPEUTICS, LLC	 		 	LUPIN LTD.
					
	By:	 	/s/ Timothy P. Walbert	 		 	By:	 	/s/ Nilesh Gupta
		 	Name:	 	Timothy P. Walbert	 		 		 	Name:	 	Nilesh Gupta
		 	Title:	 	Chairman, President & CEO	 		 		 	Title:	 	Managing Director
					
		 		 		 		 	LUPIN PHARMACEUTICALS, INC.
						
		 		 		 		 	By:	 	 
		 		 		 		 	Name:	 		 	
		 		 		 		 	Title:	 		 	

  

			
	Confidential Settlement Agreement	  	Page 29 of 36

 EXECUTION VERSION 

 

 IN WITNESS HEREOF, the Parties have caused their duly authorized representatives to execute
this Settlement Agreement to be effective as of the Effective Date. 
  

													
	HORIZON THERAPEUTICS, LLC	 		 	LUPIN LTD.
					
	By:	 	 	 		 	By:	 	 
		 	Name:	 		 		 		 	Name:	 	
		 	Title:	 		 		 		 	Title:	 	
					
		 		 		 		 	LUPIN PHARMACEUTICALS, INC.
						
		 		 		 		 	By:	 	/s/ Sean Moriarty
		 		 		 		 	Name:	 	Sean Moriarty
		 		 		 		 	Title:	 	Secretary

  

			
	Confidential Settlement Agreement	  	Page 29 of 36

 EXECUTION VERSION 

 

 Exhibit A 

IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF NEW JERSEY 
  

			
	 HORIZON THERAPEUTICS, LLC,
  

Plaintiff,
  

vs.
  

LUPIN LTD. and LUPIN
 PHARMACEUTICALS, INC.,

 
 Defendants.
	 	Civil Action No. 1:15-cv-7624-RBK-JS
		
	 HORIZON THERAPEUTICS, LLC,
  

Plaintiff,
  

vs.
  

LUPIN LTD. and LUPIN
 PHARMACEUTICALS, INC.,

 
 Defendants.
	 	Civil Action No. 1:16-cv-4438-RBK-JS

 STIPULATION AND [PROPOSED] ORDER OF DISMISSAL 

WITHOUT PREJUDICE PURSUANT TO FED. R. CIV. P. 41(a) 

Pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure, Plaintiff Horizon Therapeutics, LLC, and Defendants Lupin Limited
and Lupin Pharmaceuticals, Inc., hereby stipulate that the above-captioned actions, including all claims, counterclaims and defenses, are hereby dismissed in their entirety without prejudice. 

Dated: 

  

			
	Confidential Settlement Agreement	  	Page 30 of 36

 EXECUTION VERSION 

 

			
	      
	  	      

	 John E. Flaherty
 Ravin R. Patel

McCARTER & ENGLISH LLP
 Four Gateway Center 100 Mulberry
St.
 Newark, NJ 07102
 (973)
622-4444
	  	 Michael E. Patunas
 PATUNAS LAW LLC

24 Commerce Street, Suite 606
 Newark, New Jersey 07102 (973) 396-8740

	Attorneys for Plaintiff Horizon Therapeutics, LLC	  	Attorney for Defendants Lupin Ltd and Lupin Pharmaceuticals, Inc.
		
		  	 SO ORDERED on this                  day of

                          
                    , 2018

		
		  	      

		  	 ROBERT B. KUGLER
 UNITED STATES
DISTRICT JUDGE

  

			
	Confidential Settlement Agreement	  	Page 31 of 36

 EXECUTION VERSION 

 

 Exhibit B 

IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF NEW JERSEY 
  

			
	 HORIZON THERAPEUTICS, LLC,
  

Plaintiff,
  

vs.
  

LUPIN LTD. and LUPIN
 PHARMACEUTICALS, INC.,

 
 Defendants.
	  	Civil Action No. 2:17-cv-5900-KM-MAH

 STIPULATION AND [PROPOSED] ORDER OF DISMISSAL 

WITHOUT PREJUDICE PURSUANT TO FED. R. CIV. P. 41(a) 

Pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure, Plaintiff Horizon Therapeutics, LLC, and Defendants Lupin Limited
and Lupin Pharmaceuticals, Inc., hereby stipulate that the above-captioned action, including all claims, counterclaims and defenses, are hereby dismissed in their entirety without prejudice. 

Dated: 
  

			
	      
	  	      

	 John E. Flaherty
 Ravin R. Patel

McCARTER & ENGLISH LLP
 Four Gateway Center 100 Mulberry
St.
 Newark, NJ 07102
 (973)
622-4444
 Attorneys for Plaintiff Horizon Therapeutics, LLC
	  	 Michael E. Patunas
 PATUNAS LAW LLC

24 Commerce Street, Suite 606
 Newark, New Jersey 07102

(973) 396-8740

Attorney for Defendants Lupin Ltd and Lupin Pharmaceuticals, Inc.

		  	 SO ORDERED on this                  day of

                          
                    , 2018

  

			
	Confidential Settlement Agreement	  	Page 32 of 36

 EXECUTION VERSION 

 

			
		
		  	      

		  	 KEVIN MCNULTY
 UNITED STATES DISTRICT
JUDGE

  

			
	Confidential Settlement Agreement	  	Page 33 of 36

 EXECUTION VERSION 

 

 Exhibit C 

2018-1225 
  

 
  

In the 
 United States Court of
Appeals 
 For the Federal Circuit 
  

 
 HORIZON
THERAPEUTICS, LLC, 

                       
                         Appellant, 

v. 
 LUPIN LTD. AND LUPIN
PHARMACEUTICALS, INC., 

                       
                         Appellee. 

 
  

Appeal from the United States Patent and Trademark Office 

in case no. IPR2016-00829, Judge Lora M. Green, 

Judge Deborah Katz and Judge Toni R. Scheiner. 

LUPIN LTD.’S AND LUPIN PHARMACEUTICALS, INC.’S UNOPPOSED MOTION TO WITHDRAW AS APPELLEES 

 

			
	 William M. Jay
 GOODWIN PROCTER LLP

901 New York Ave. NW
 Washington, DC 20001

Tel.: 202.346.4000
 Fax.: 202.346.4444
	  	 Elizabeth J. Holland
 Robert V. Cerwinski

Cynthia Lambert Hardman
 Tiffany Mahmood

GOODWIN PROCTER LLP
 The New York Times Building

620 Eighth Avenue
 New York, NY 10018

Tel.: 212-813-8800

Fax.:
212-355-3333

  

			
	Confidential Settlement Agreement	  	Page 34 of 36

 EXECUTION VERSION 

 

			
	Date: June     , 2018	  	Counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.

  

			
	Confidential Settlement Agreement	  	Page 35 of 36

 EXECUTION VERSION 

 

 Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. respectfully move to
withdraw as Appellees and named parties from this appeal. Appellant Horizon Therapeutics, LLC consents to the withdrawal. Appellees’ withdrawal is appropriate because the parties have reached a confidential
settlement agreement.The parties have agreed to bear their own costs. 
 Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. therefore
respectfully request that the Court grant them leave to withdraw as Appellees. 
  

							
	June     , 2018	 		 		 	Respectfully submitted,
				
		 		 		 	 
		 		 		 	 William M. Jay
 Goodwin Procter LLP

901 New York Avenue NW
 Washington, DC 20001

Tel.: 202.346.4000
 Fax.: 202.346.4444

  

			
	Confidential Settlement Agreement	  	Page 36 of 36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]